Bridging the Gap: Index Volume [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

12th World AIDS Conference

PCR * perspective 145

SKeyword Abstr
A comparative study of,p24 antigen and HIV-lgA for early dia
n/False negative HIV1- in the first two months of live of a child
merase chain reaction ( )/Screening of HIV in 740 Brazilian bl
ubtype and quantitative RNA assays in HIV-1 infected childre
uation/Should plasma be used to target CMV prophylaxis in
of HIV-1 subtypes by a and a branched DNA technique/Qua
pstein-Barr virus (EBV) of CSF: Is it useful in the diagnosis of
ions: Diagnosis by CSF /Necropsy-proven Toxoplasma ecep
merase chain reaction ( ) on cerebrospinal fluid (CSF) in patie
s of Immunex, Kemron, Pearl Omega and Polyatomic Apheresis (
nd social obligations: Peasant food security in the context of AID
n: 12 years of follow-up/ Pediatric AIDS in a Brazilian population: 1

act
42114
42125
42134
42171
44242
60230
60496
60647
60734
474*/44140
24159
12179

-Keyword: The experience of the
en treated at sites of the
ong-term follow-up of pediatric
igh viral burden in rapid
ce with ritonavir in HIV+
tations in a Puertorican
haracterization of the
CSF HIV-1 viral load in
therapy with ritonavir in
V/Disclosure model for
elates with virus load in
s and providers in AIDS
n infectious episodes in
f abacavir in a phase III
reatment adherence in
uidelines (ATMMGs) of
to PCR for diagnosis of
edical students on their
A) in plasma samples in
ssion of HIV infection in
t achieve a reduction in

Abstract--

Study Group/Treatment educati 32441
AIDS Clinical Trials Group (PAC 32444
AIDS Clinical Trials Group (PAC 12160
HIV-1 disease/Heart, lung, and i 12171
patients/Experience with ritonav 12173
HIV infected population/Neurolo 12181
patients attending the University 12183
patients with advanced HIV dise 12253
HIV infection/Combination antir 12296
patients living with HIV/Disclosu 14255
HIV infection/Plasma L-selectin I 21115
and family programs/Collaborati 24356
AIDS/Role of mannon-biding pr 31164
study/Correlation of phenotypic 232*/32283
HIV: Identifying the issues from p 32438
HIV infection/Antiretroviral thera 32439
HIV-1 infection and quantificatio 32442
clinic rotation/Pilot study on attit 32447
cases/Analyzes of HIV-1 viral lo 42178
population/Nutritional and clinic 42366
AIDS?/Mandatory HIV testing of 44107

eness among women in peri-urban areas of Entebbe, Uganda/Pro 60046
ers in Nairobi urban and slums/Promoting AIDS preven 60456
voluntary HIV testing in population in Uganda/Determi 60985
e reports/Tuberculosis pericarditis as first manifestation of AIDS: 32219
nti-HIV substance from Perilla frutescens Britton, mint plant/Purifi 41197
update/North Thailand Perinatal HIV Prevention Trial (NTPHPT): 12250
985-1996/The National HIV Surveillance Program: Cana 13221
udies (the International HIV Group)/Mode of delivery an 23275
on study in Zimbabwe/ HIV transmission: Ethical dilem 44124
eatment in reduction of perinatal HIV-1 transmission/The potenti 12156
ne to reduce the risk of transmission of HIV infection in t 12157
al abnormalities predict HIV infection in Brazilian infants? 174*/12169
vudine (ZDV) to reduce HIV-1 transmission in PACTG 07 12233
perienced children with HIV-1 infection/Response to rito 12254
s in the largest ongoing HIV study in India/Modified ACT 12408
ong children with recent HIV-1 infection/Increase based 13362
urvival associated with HIV-1 subtype E infection, Bang 13366
eumonia in infants with HIV infection/Incidence and risk 13367
sease progression in a HIV cohort: The women and infa 13368
Disease progression in HIV-1 infection/Disease progres 13371
hylaxis/Risk factors for HIV transmission in women/infa 462*/23265
e treatment/Decreased HIV-1 transmission following ele 23272
opportunities to reduce HIV transmission: Maternal and 458*/23273
esarean section" and transmission of the human immu 23274
cted women and risk of transmission/Induced /-chemo 23279
4 states/Prevention of transmission in the US: A popula 23282
mmunity based study of transmission of HIV-1 and HIV-2 23284
elow 3% in the German cohorts/Combining ZVD treatm 23291
nters: Prevention of HIV transmission/Needs assessmen 23294
a/Zidovudine (ZDV) for prophylaxis starting on week 24 i 23299
acy of prenatal care and zidovudine use to prevent HIV tr 23304
ffective in preventing HIV-1 infection in newborns deliv 23305
revention/Status of the HIV epidemic in the United State 23306
ia model/Prevention of transmission: IHO-Wadia model 23309
mpact of zidovudine on HIV transmission in Mallorca Isla 23314
renatal HIV testing and treatment and intervention strate 23317
ovudine reduces HIV-1 transmission even if only the oral 23326
ility in HIV prevention of transmission/Social vulnerability 23328
BV)/Heterosexual and transmission of HIV-1: Associati 527*/23347
svirus 6 in children with HIV-1 infection/Primary infectio 31201
late oral ZDV to reduce HIV transmission, Bangkok/Saf 32341
apy continue to reduce HIV transmission? The North Ca 33162
urse oral ZDV to reduce HIV transmission, Thailand/Ran 30*/33163
A for early diagnosis of HIV infection in Brazilian infants/ 42114
osis and quantitation of HIV in Thailand/Evaluation of HI 42124
nt guidelines to reduce transmission of HIV/Health care 460*/42210
ates activities to reduce HIV transmission: Activities withi 43186
of women to determine provider practice regarding HIV 43561
/State efforts to reduce HIV transmission/State efforts to 44105
with a high incidence of HIV infection/Collaborative appr 60169
ong-term survivors with HIV/Autopsy findings in long-ter 60717
rammes for preventing transmission of HIV/Evaluating t 60784
regnancy in reducing tranmission of HIV-1/Impact of tr 60900
e and HIV-1 infection in perinatally-exposed infants/CCR5 genot 215*/13365
ct HIV-1 progression in perinatally infected children/Pertussis im 12170

n living with HIV/AIDS/ Peer support among HIV positive women
airobi slums, in Kenya/ for young people living with
g program for HIV/AIDS peer support counsellors/A training progr
zed trial comparing SC, PEG, CIV IL2 with AZT + ddl/IL2 in HIV pat
HIV-1 seroprevalence/ Pelvic inflammatory disease among wome
nstitute (NYSDOH/AI)/ exam performance improvement ca
men/Clinical course of pelvic inflammatory disease (PID) in HIV+
t associated with acute inflammatory disease in HIV-infecte
nfected women/Acute inflammatory disease associated wi
of methylphenidate and pemoline /Psychostimulants for fatigue in t
ncy HIV Study (WIHS)/ Penetrance of combination antiretroviral t
brain barrier/Stavudine penetrates the blood-brain barrier/Stavud
n/AIDS and community penetration through leaders women/AID
articipate in a routine penicillin prophylaxis program in Surabay
o HIV/AIDS at the state penitentiary in Metro Manila/The psychos
ive actions inside of the /Continuous education and c
he role of the police and authorities in the AIDS preve
D-pentavalent V3 loop penta-peptide conjugate vaccine on redu
nfected children - The PENTA 4 Trial/A randomised double blind
bo controlled trial - The I trial/Parents attitudes to their HIV
The role of aerosolized pentamidine prophylaxis in the era of com
unit in Brazil/Inhalatory: handling alternative form to
mationally constrained congeners as anti-pneumoc
onal cell line viability/A pentapeptide from HIV-1 gp120 V3 region
s ulcers in HIV patients/ Pentoxifylline for the treatment of aphtous
couples/Awareness of PEP and viral suppressive therapy have litt
exposure prophylaxis ( ) for occupational exposures to HIV/T
-exposure prevention ( ) following high risk sexual or injection
exposure prophylaxis ( ) following high risk sexual exposure:
-exposure prophylaxis ( ): A prospective study of HIV-exposed
exposure prophylaxis ( ) for episodic high-risk sexual behavior
-exposure prophylaxis ( )/French physicians experiences and
ty hospital setting/The Team: A multidisciplinary team appro
ure prophylaxis hotline ( PEPLine )/National clinicians' post-exposu
r of HIV-1 protease and peptide derivatives of Vif inhibit Gag-Pol pr
Discordances between serotyping and HMA genotyping i
osting with a synthetic polymer from the C4 region of SIV
munoassay/Universal for detection of HIV-1 group M and
od spots (DBS) and V3 serotyping in Thailand/Determina
Seroreactivity to HIV-1 peptides in pregnant women in Porto Aleg
se of V3 and gp41 env /Improved specificity for serotypi
ry influences of a-MSH on HIV-1 expression in monocyti
V-1 protease inhibitors/ Peptidic "tongs" constrained by a rigid spa
y on patients at the "Eva Per6n " Teaching Hospital (HEEP)/HIV inf
le sex workers in Lima, Peru /A new system monitoring and evalua
iving with HIV/AIDS in /Advocacy workshops: Creating effec
h AIDS (PWA) in Lima, /Promotion and defense of human rig

24284
33284
24368
41229
23348
60209
32128
32135
60882
22429
22380
12354
34122
60355
23543
24281
33411
21209
12249
12261
22182
22474
31212
60334
60371
14146
246*/33171
249*/33172
33173
33175
576*/33183
248*/33192
60200
33185
377*/11130
11193
11241
41104
161*/42101
11202
13121
60685
12289
43153
33595
34306
44141

binant genotypes from infected infants in Tanzania/V
ailure to thrive among HIV-infected children in Puerto
m birth to school-age in HIV-1 infected children/Patter
NYC)/Aging cohort of HIV-infected children in New Y
disease progression in infected infants/Virus detectio
e transient infections in exposed infants/Viral and host
dictor of HIV infection in exposed children/Serum y-glo
dictor of HIV infection in exposed children/Serum y-glo
ent ages among HIV-1 and post-natally infected Keny
disease and advanced periodontal disease/Gingival fluid (GF): P
valence and severity of disease in a Brazilian populati
ments from the patients' perspective "/French national study "Life

erapies naives/Patient
/Listening to a patient's
adolescents/A healthy
retroviral therapy/New
Pacific region - A PWA
on: An ecopsychosocial
A qualitative ecological
bia from a development
s not dispensable: The
sitive youth: A historical
HIV/AIDS: A Hong Kong
on from a human rights
ns from a human rights

of clinical disease and care in
may provide more than a hum
towards sex and sexuality am
in the treatment of multi drug r
/Use of herbal and holistic the
/Toward a new paradigm for
on HIV+ patients and proteas
/Tackling HIV/AIDS in rural Z
of five HIV+ affected individua
of Bay area young positives/
/Treatment advocacy for peo
in Honduras, Central America
/Care for people living with HI

13115
13237
13361
175*/13363
13369
23312
42399
42407
60790
23401
32252
12450
12452
12457
13540
22125
22487
23375
32365
33502
34131
34246
34279
44121
44161